Open AccessLong-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
Author(s) -
Robin Ebbestad,
Mazdak Sanaei Nurmi,
Sigrid Lundberg
Publication year - 2022
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000525001
Subject(s) - microhematuria , medicine , nephropathy , renal function , cohort , kidney disease , nephrology , microalbuminuria , urology , proteinuria , gastroenterology , kidney , endocrinology , diabetes mellitus
Within 30 years, 20-50% of IgA nephropathy (IgAN) patients progress to end-stage kidney disease (ESKD). Identifying these patients can be difficult since renal function may deteriorate after being stable for years. The International IgAN Risk Prediction tool (IgAN-RPT) combines histologic lesions and clinical risk factors to predict renal outcome up to 5 or 7 years of follow-up. The clinical value beyond 7 years is unknown and microhematuria data has not been assessed.